Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIVE Follow-up long-term safety study of intracerebroventricular anaerobic dopamine in Parkinson disease
2025-522261-30-00Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of A-dopamine in Parkinson's disease (PD), sponsored by CHU de Lille. Started Oct 2025; status: completed.
02
Drugs
A-dopamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-522261-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522261-30-00.